The first inferior vena cava (IVC) filter lawsuits against Cook Medical will be tried as bellwether cases next month, and may set the tone for similar cases filed against C.R. Bard that will begin in mid-2017.
The Cook IVC multidistrict litigation (MDL) was established in October 2014 in the Southern District of Indiana.
The lawsuits consolidated into the MDL make similar allegations:
IVC filters are medical devices placed between the proximal vessels of the lower extremities and the right side of the heart.
They help prevent pulmonary embolism by catching blood clots and preventing them from traveling to the lungs.
Over the past 30 years, the use of the IVC filter has steadily increased.
While approximately 2,000 filters were implanted in patients in the U.S. in 1979, by 1990, over 120,000 IVC filters had been placed.
At the end of the decade, nearly 50,000 IVC filters were being implanted each year.
Since 2005, the U.S. Food and Drug Administration (FDA) has received more than 900 reports of adverse events connected to IVC filters.
According to the FDA, the majority of IVC filters are not retrieved despite the risk of increased fracture, embolism, and IVC wall penetration.
Common complications associated with IVC filters left in the body for long periods of time include:
A 2013 JAMA Internal Medicine report noted that an attempt is made to remove only about 10.5 percent of all IVC filters implanted, and concluded that this low retrieval rate, combined with other factors, resulted in less-than-optimal outcomes due to high rates of venous thromboembolism (VTE).
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Weis Market Inc., a Mid-Atlantic food retailer based in Sunbury, Pennsylvania, has recalled its 48-ounce containers of Weis Quality Brownie Moose Tracks Ice Cream because the product may contain traces of egg, an allergen not declared on the ingredient statement label, according to the FDA.
Marlex Pharmaceuticals, Inc., of New Castle, Delaware, has announced a voluntary, consumer-level recall of one lot of Digoxin Tablets USP, 0125mg, as well as one lot of Digoxin Tablets USP, 0.25mg, because the labels of both products have been mixed up, according to the FDA.